The majority of active agents do not readily permeate into brain due to the presence of the blood-brain barrier and blood-cerebrospinal fluid barrier. Currently, the most innovative and promising non-invasive strategy in brain delivery is the design and preparation of nanocarriers, which can move through the brain endothelium. Niosomes can perform brain delivery, in fact polysorbates, can act as an anchor for apolipoprotein E from blood plasma. The particles mimic LDL and interact with the LDL receptor leading to the endothelial cells uptake. The efficacy of niosomes for anticancer therapeutic applications was correlated to their physicochemical and drug delivery properties. Dimensions and z-potential were characterized using dynamic light scattering and asymmetric flow-field fractionation system. Lipid bilayer was characterized measuring the fluidity, polarity and microviscosity by fluorescent probe spectra evaluation. Morphology and homogeneity were characterized using atomic force microscopy. Physicochemical stability and serum stability (45% v/v fetal bovine and human serum) were evaluated as a function of time using dynamic light scattering. U87-MG human glioblastoma cells were used to evaluate vesicle cytotoxicity and internalisation efficiency. From the obtained data, the systems appear useful to perform a prolonged (modified) release of biological active substances to the central nervous system.

Niosomal approach to brain delivery: Development, characterization and in vitro toxicological studies / Ingallina, Cinzia; Rinaldi, Federica; Bogni, A.; Ponti, J.; Passeri, Daniele; Reggente, Melania; Rossi, Marco; Kinsner Ovaskainen, A.; Mehn, D.; Rossi, F.; Botta, Bruno; Carafa, Maria; Marianecci, Carlotta. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - STAMPA. - 511:2(2016), pp. 969-982. [10.1016/j.ijpharm.2016.08.002]

Niosomal approach to brain delivery: Development, characterization and in vitro toxicological studies

INGALLINA, CINZIA;RINALDI, FEDERICA;PASSERI, Daniele;REGGENTE, MELANIA;ROSSI, Marco;BOTTA, Bruno;CARAFA, Maria;MARIANECCI, CARLOTTA
Ultimo
2016

Abstract

The majority of active agents do not readily permeate into brain due to the presence of the blood-brain barrier and blood-cerebrospinal fluid barrier. Currently, the most innovative and promising non-invasive strategy in brain delivery is the design and preparation of nanocarriers, which can move through the brain endothelium. Niosomes can perform brain delivery, in fact polysorbates, can act as an anchor for apolipoprotein E from blood plasma. The particles mimic LDL and interact with the LDL receptor leading to the endothelial cells uptake. The efficacy of niosomes for anticancer therapeutic applications was correlated to their physicochemical and drug delivery properties. Dimensions and z-potential were characterized using dynamic light scattering and asymmetric flow-field fractionation system. Lipid bilayer was characterized measuring the fluidity, polarity and microviscosity by fluorescent probe spectra evaluation. Morphology and homogeneity were characterized using atomic force microscopy. Physicochemical stability and serum stability (45% v/v fetal bovine and human serum) were evaluated as a function of time using dynamic light scattering. U87-MG human glioblastoma cells were used to evaluate vesicle cytotoxicity and internalisation efficiency. From the obtained data, the systems appear useful to perform a prolonged (modified) release of biological active substances to the central nervous system.
AFM; Asymmetric flow-field fractionation system; Brain delivery; Cell internalization; Citotoxicity; Niosomes; 3003
01 Pubblicazione su rivista::01a Articolo in rivista
Niosomal approach to brain delivery: Development, characterization and in vitro toxicological studies / Ingallina, Cinzia; Rinaldi, Federica; Bogni, A.; Ponti, J.; Passeri, Daniele; Reggente, Melania; Rossi, Marco; Kinsner Ovaskainen, A.; Mehn, D.; Rossi, F.; Botta, Bruno; Carafa, Maria; Marianecci, Carlotta. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - STAMPA. - 511:2(2016), pp. 969-982. [10.1016/j.ijpharm.2016.08.002]
File allegati a questo prodotto
File Dimensione Formato  
2016_Ingallina_IntJPharm_511_2016_p969.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.53 MB
Formato Adobe PDF
2.53 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/894249
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 25
social impact